Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
AssigneeUcb Biopharma Sprl
InventorsAdam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
Claims6
A method for monitoring the effect of a medicament for treating a disease mediated by increased levels of IL-17A comprising:
- (a) administering a medicament comprising an anti-IL-17A/F antibody to a subject suffering from a disease mediated by increased levels of IL-17A;
- (b) measuring the level of mRNA expression of lipocalin 2 or the level of lipocalin 2 protein in a test sample of body fluid or tissue obtained from the subject and detecting a decrease in the level of mRNA expression of lipocalin 2 or the level of lipocalin 2 protein compared to the level of mRNA expression of lipocalin 2 or the level of lipocalin 2 protein prior to administration of the medicament;
- and
- (c) administering at least one additional dose of the medicament comprising the anti-IL-17A/F antibody to the subject.
A method for treating an IL-17 mediated disease in a patient comprising administering an effective dose of an IL-17 inhibitor to said patient, wherein the effective dose is determined by (a) comparing the level of lipocalin 2 expression in a test sample of a body fluid or tissue from said patient to a reference value;
- and (b) selecting a suitable dose of a medicament comprising an IL-17 inhibitor based on the comparison made in step (a).
Dependencies are inferred from the claim text.